{"entity":{"type":"insider","cik":"0001422339","url":"/insider/0001422339","json_url":"/insider/0001422339.json","name":"SVLSF IV, LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":109,"n_filings":22,"first":"2009-09-17","last":"2019-04-10","span_basis":"filed_date"},"name_variants":[{"name":"SVLSF IV, LLC","source":"filing","n_filings":22,"first_seen":"2009-09-17","last_seen":"2019-04-10"}],"transactions":[{"id":7775527,"accession":"0000899243-19-010492","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-19-010492","line_url":"/filing/0000899243-19-010492","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV Life Sciences Fund IV (GP), L.P.; SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SVLSF IV, LLC; SV LIFE SCIENCES FUND IV, L.P.","owner_display_name":"SV Life Sciences Fund IV (GP), L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13531.0,"shares_display":"13,531","price_per_share":29.3952,"price_display":"29.40","price_state":"stated","total_value":397746.4512,"total_display":"397,746.45","total_whole":"397,746","shares_owned_after":1672105.0,"shares_owned_after_display":"1,672,105","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-04-10","filed_date":"2019-04-10","scope":"insider","n_lines":2},{"id":7775523,"accession":"0000899243-19-010492","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-19-010492","line_url":"/filing/0000899243-19-010492","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV Life Sciences Fund IV (GP), L.P.; SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SVLSF IV, LLC; SV LIFE SCIENCES FUND IV, L.P.","owner_display_name":"SV Life Sciences Fund IV (GP), L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13669.0,"shares_display":"13,669","price_per_share":28.5305,"price_display":"28.53","price_state":"stated","total_value":389983.4045,"total_display":"389,983.40","total_whole":"389,983","shares_owned_after":1685262.0,"shares_owned_after_display":"1,685,262","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-04-09","filed_date":"2019-04-10","scope":"insider","n_lines":2},{"id":7775519,"accession":"0000899243-19-010492","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-010492","line_url":"/filing/0000899243-19-010492","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV Life Sciences Fund IV (GP), L.P.; SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SVLSF IV, LLC; SV LIFE SCIENCES FUND IV, L.P.","owner_display_name":"SV Life Sciences Fund IV (GP), L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22800.0,"shares_display":"22,800","price_per_share":29.4919,"price_display":"29.49","price_state":"stated","total_value":672415.32,"total_display":"672,415.32","total_whole":"672,415","shares_owned_after":1698554.0,"shares_owned_after_display":"1,698,554","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-04-08","filed_date":"2019-04-10","scope":"insider","n_lines":2},{"id":8690669,"accession":"0000899243-19-009640","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-19-009640","line_url":"/filing/0000899243-19-009640","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SV LIFE SCIENCES FUND IV, L.P.; SV Life Sciences Fund IV (GP), L.P.; SVLSF IV, LLC","owner_display_name":"SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9141.0,"shares_display":"9,141","price_per_share":28.7638,"price_display":"28.76","price_state":"stated","total_value":262929.8958,"total_display":"262,929.90","total_whole":"262,930","shares_owned_after":1720725.0,"shares_owned_after_display":"1,720,725","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-04-02","filed_date":"2019-04-02","scope":"insider","n_lines":2},{"id":8690664,"accession":"0000899243-19-009640","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-19-009640","line_url":"/filing/0000899243-19-009640","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SV LIFE SCIENCES FUND IV, L.P.; SV Life Sciences Fund IV (GP), L.P.; SVLSF IV, LLC","owner_display_name":"SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":52831.0,"shares_display":"52,831","price_per_share":27.6582,"price_display":"27.66","price_state":"stated","total_value":1461210.3642,"total_display":"1,461,210.36","total_whole":"1,461,210","shares_owned_after":1729613.0,"shares_owned_after_display":"1,729,613","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-04-01","filed_date":"2019-04-02","scope":"insider","n_lines":2},{"id":8690659,"accession":"0000899243-19-009640","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-009640","line_url":"/filing/0000899243-19-009640","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SV LIFE SCIENCES FUND IV, L.P.; SV Life Sciences Fund IV (GP), L.P.; SVLSF IV, LLC","owner_display_name":"SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":35102.0,"shares_display":"35,102","price_per_share":28.396,"price_display":"28.40","price_state":"stated","total_value":996756.392,"total_display":"996,756.39","total_whole":"996,756","shares_owned_after":1780986.0,"shares_owned_after_display":"1,780,986","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-29","filed_date":"2019-04-02","scope":"insider","n_lines":2},{"id":8186297,"accession":"0000899243-19-009178","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-19-009178","line_url":"/filing/0000899243-19-009178","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SVLSF IV, LLC; SV LIFE SCIENCES FUND IV, L.P.; SV Life Sciences Fund IV (GP), L.P.","owner_display_name":"SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":36665.0,"shares_display":"36,665","price_per_share":27.801,"price_display":"27.80","price_state":"stated","total_value":1019323.665,"total_display":"1,019,323.66","total_whole":"1,019,324","shares_owned_after":1815119.0,"shares_owned_after_display":"1,815,119","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-28","filed_date":"2019-03-28","scope":"insider","n_lines":2},{"id":8186292,"accession":"0000899243-19-009178","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-19-009178","line_url":"/filing/0000899243-19-009178","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SVLSF IV, LLC; SV LIFE SCIENCES FUND IV, L.P.; SV Life Sciences Fund IV (GP), L.P.","owner_display_name":"SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":57917.0,"shares_display":"57,917","price_per_share":29.0592,"price_display":"29.06","price_state":"stated","total_value":1683021.6864,"total_display":"1,683,021.69","total_whole":"1,683,022","shares_owned_after":1850772.0,"shares_owned_after_display":"1,850,772","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-27","filed_date":"2019-03-28","scope":"insider","n_lines":2},{"id":8186286,"accession":"0000899243-19-009178","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-009178","line_url":"/filing/0000899243-19-009178","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SVLSF IV, LLC; SV LIFE SCIENCES FUND IV, L.P.; SV Life Sciences Fund IV (GP), L.P.","owner_display_name":"SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30093.0,"shares_display":"30,093","price_per_share":29.6975,"price_display":"29.70","price_state":"stated","total_value":893686.8675,"total_display":"893,686.87","total_whole":"893,687","shares_owned_after":1907090.0,"shares_owned_after_display":"1,907,090","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-26","filed_date":"2019-03-28","scope":"insider","n_lines":2},{"id":8543834,"accession":"0000899243-19-008526","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-008526","line_url":"/filing/0000899243-19-008526","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV LIFE SCIENCES FUND IV, L.P.; SVLSF IV, LLC; SV Life Sciences Fund IV (GP), L.P.; SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.","owner_display_name":"SV LIFE SCIENCES FUND IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":262470.0,"shares_display":"262,470","price_per_share":26.7,"price_display":"26.70","price_state":"stated","total_value":7007949.0,"total_display":"7,007,949.00","total_whole":"7,007,949","shares_owned_after":1936352.0,"shares_owned_after_display":"1,936,352","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-18","filed_date":"2019-03-20","scope":"insider","n_lines":2},{"id":8543698,"accession":"0000899243-19-006369","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-19-006369","line_url":"/filing/0000899243-19-006369","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV LIFE SCIENCES FUND IV, L.P.; SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SVLSF IV, LLC; SV Life Sciences Fund IV (GP), L.P.","owner_display_name":"SV LIFE SCIENCES FUND IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":32332.0,"shares_display":"32,332","price_per_share":23.0365,"price_display":"23.04","price_state":"stated","total_value":744816.118,"total_display":"744,816.12","total_whole":"744,816","shares_owned_after":2191576.0,"shares_owned_after_display":"2,191,576","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-05","filed_date":"2019-03-06","scope":"insider","n_lines":2},{"id":8543689,"accession":"0000899243-19-006369","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-006369","line_url":"/filing/0000899243-19-006369","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV LIFE SCIENCES FUND IV, L.P.; SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SVLSF IV, LLC; SV Life Sciences Fund IV (GP), L.P.","owner_display_name":"SV LIFE SCIENCES FUND IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":43378.0,"shares_display":"43,378","price_per_share":22.907,"price_display":"22.91","price_state":"stated","total_value":993659.846,"total_display":"993,659.85","total_whole":"993,660","shares_owned_after":2223015.0,"shares_owned_after_display":"2,223,015","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-04","filed_date":"2019-03-06","scope":"insider","n_lines":2},{"id":8114838,"accession":"0000899243-19-004359","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-19-004359","line_url":"/filing/0000899243-19-004359","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV LIFE SCIENCES FUND IV, L.P.; SV Life Sciences Fund IV (GP), L.P.; SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SVLSF IV, LLC","owner_display_name":"SV LIFE SCIENCES FUND IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":172543.0,"shares_display":"172,543","price_per_share":20.6,"price_display":"20.60","price_state":"stated","total_value":3554385.8,"total_display":"3,554,385.80","total_whole":"3,554,386","shares_owned_after":2265196.0,"shares_owned_after_display":"2,265,196","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-21","filed_date":"2019-02-21","scope":"insider","n_lines":2},{"id":8114836,"accession":"0000899243-19-004359","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-19-004359","line_url":"/filing/0000899243-19-004359","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV LIFE SCIENCES FUND IV, L.P.; SV Life Sciences Fund IV (GP), L.P.; SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SVLSF IV, LLC","owner_display_name":"SV LIFE SCIENCES FUND IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":23235.0,"shares_display":"23,235","price_per_share":20.0159,"price_display":"20.02","price_state":"stated","total_value":465069.4365,"total_display":"465,069.44","total_whole":"465,069","shares_owned_after":2432975.0,"shares_owned_after_display":"2,432,975","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-20","filed_date":"2019-02-21","scope":"insider","n_lines":2},{"id":8114834,"accession":"0000899243-19-004359","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-004359","line_url":"/filing/0000899243-19-004359","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV LIFE SCIENCES FUND IV, L.P.; SV Life Sciences Fund IV (GP), L.P.; SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SVLSF IV, LLC","owner_display_name":"SV LIFE SCIENCES FUND IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18420.0,"shares_display":"18,420","price_per_share":20.7328,"price_display":"20.73","price_state":"stated","total_value":381898.176,"total_display":"381,898.18","total_whole":"381,898","shares_owned_after":2455569.0,"shares_owned_after_display":"2,455,569","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-19","filed_date":"2019-02-21","scope":"insider","n_lines":2},{"id":8021831,"accession":"0000899243-19-000686","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-19-000686","line_url":"/filing/0000899243-19-000686","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SVLSF IV, LLC; SV Life Sciences Fund IV (GP), L.P.; SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SV LIFE SCIENCES FUND IV, L.P.","owner_display_name":"SVLSF IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2599.0,"shares_display":"2,599","price_per_share":20.412,"price_display":"20.41","price_state":"stated","total_value":53050.788,"total_display":"53,050.79","total_whole":"53,051","shares_owned_after":2473481.0,"shares_owned_after_display":"2,473,481","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-07","filed_date":"2019-01-07","scope":"insider","n_lines":2},{"id":8021829,"accession":"0000899243-19-000686","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-000686","line_url":"/filing/0000899243-19-000686","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SVLSF IV, LLC; SV Life Sciences Fund IV (GP), L.P.; SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SV LIFE SCIENCES FUND IV, L.P.","owner_display_name":"SVLSF IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1700.0,"shares_display":"1,700","price_per_share":20.013,"price_display":"20.01","price_state":"stated","total_value":34022.1,"total_display":"34,022.10","total_whole":"34,022","shares_owned_after":2476008.0,"shares_owned_after_display":"2,476,008","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-03","filed_date":"2019-01-07","scope":"insider","n_lines":2},{"id":8375398,"accession":"0000899243-19-000172","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-19-000172","line_url":"/filing/0000899243-19-000172","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV LIFE SCIENCES FUND IV, L.P.; SVLSF IV, LLC; SV Life Sciences Fund IV (GP), L.P.; SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.","owner_display_name":"SV LIFE SCIENCES FUND IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200.0,"shares_display":"200","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":4000.0,"total_display":"4,000.00","total_whole":"4,000","shares_owned_after":2477661.0,"shares_owned_after_display":"2,477,661","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-02","filed_date":"2019-01-02","scope":"insider","n_lines":2},{"id":8375389,"accession":"0000899243-19-000172","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-19-000172","line_url":"/filing/0000899243-19-000172","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV LIFE SCIENCES FUND IV, L.P.; SVLSF IV, LLC; SV Life Sciences Fund IV (GP), L.P.; SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.","owner_display_name":"SV LIFE SCIENCES FUND IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25418.0,"shares_display":"25,418","price_per_share":20.004,"price_display":"20.00","price_state":"stated","total_value":508461.672,"total_display":"508,461.67","total_whole":"508,462","shares_owned_after":2477855.0,"shares_owned_after_display":"2,477,855","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-31","filed_date":"2019-01-02","scope":"insider","n_lines":2},{"id":8375383,"accession":"0000899243-19-000172","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-000172","line_url":"/filing/0000899243-19-000172","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV LIFE SCIENCES FUND IV, L.P.; SVLSF IV, LLC; SV Life Sciences Fund IV (GP), L.P.; SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.","owner_display_name":"SV LIFE SCIENCES FUND IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3734.0,"shares_display":"3,734","price_per_share":20.027,"price_display":"20.03","price_state":"stated","total_value":74780.818,"total_display":"74,780.82","total_whole":"74,781","shares_owned_after":2502571.0,"shares_owned_after_display":"2,502,571","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-28","filed_date":"2019-01-02","scope":"insider","n_lines":2},{"id":6538269,"accession":"0000899243-18-031591","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-031591","line_url":"/filing/0000899243-18-031591","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"SV Life Sciences Fund IV (GP), L.P.; SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SV LIFE SCIENCES FUND IV, L.P.; SVLSF IV, LLC","owner_display_name":"SV Life Sciences Fund IV (GP), L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2136.0,"shares_display":"2,136","price_per_share":20.018,"price_display":"20.02","price_state":"stated","total_value":42758.448,"total_display":"42,758.45","total_whole":"42,758","shares_owned_after":2506202.0,"shares_owned_after_display":"2,506,202","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-19","filed_date":"2018-12-21","scope":"insider","n_lines":2},{"id":4127884,"accession":"0001235802-17-000022","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001235802-17-000022","line_url":"/filing/0001235802-17-000022","is_derivative":false,"issuer_cik":"0001172861","issuer_name":"ENTELLUS MEDICAL INC","issuer_ticker":"ENTL","issuer_name_source":null,"issuer_url":"/issuer/0001172861","owner_cik":null,"owner_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.; SVLSF IV, LLC; SV LIFE SCIENCES FUND IV, L.P.; INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.; INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.; SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.","owner_display_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":533077.0,"shares_display":"533,077","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":9062309.0,"total_display":"9,062,309.00","total_whole":"9,062,309","shares_owned_after":1791070.0,"shares_owned_after_display":"1,791,070","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-01-31","filed_date":"2017-02-02","scope":"insider","n_lines":5},{"id":8793450,"accession":"0001209191-15-052371","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-15-052371","line_url":"/filing/0001209191-15-052371#line-4","is_derivative":false,"issuer_cik":"0001367381","issuer_name":"OCULAR THERAPEUTIX, INC","issuer_ticker":"OCUL","issuer_name_source":null,"issuer_url":"/issuer/0001367381","owner_cik":null,"owner_name":"SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SVLSF IV, LLC; SV LIFE SCIENCES FUND IV, L.P.; SV Life Sciences Fund IV (GP), L.P.","owner_display_name":"SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":373000.0,"shares_display":"373,000","price_per_share":22.0,"price_display":"22.00","price_state":"stated","total_value":8206000.0,"total_display":"8,206,000.00","total_whole":"8,206,000","shares_owned_after":2212607.0,"shares_owned_after_display":"2,212,607","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-06-10","filed_date":"2015-06-11","scope":"insider"},{"id":8793449,"accession":"0001209191-15-052371","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-15-052371","line_url":"/filing/0001209191-15-052371#line-3","is_derivative":false,"issuer_cik":"0001367381","issuer_name":"OCULAR THERAPEUTIX, INC","issuer_ticker":"OCUL","issuer_name_source":null,"issuer_url":"/issuer/0001367381","owner_cik":null,"owner_name":"SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SVLSF IV, LLC; SV LIFE SCIENCES FUND IV, L.P.; SV Life Sciences Fund IV (GP), L.P.","owner_display_name":"SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":373000.0,"shares_display":"373,000","price_per_share":22.0,"price_display":"22.00","price_state":"stated","total_value":8206000.0,"total_display":"8,206,000.00","total_whole":"8,206,000","shares_owned_after":2212607.0,"shares_owned_after_display":"2,212,607","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-06-10","filed_date":"2015-06-11","scope":"insider"},{"id":8793448,"accession":"0001209191-15-052371","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-15-052371","line_url":"/filing/0001209191-15-052371#line-2","is_derivative":false,"issuer_cik":"0001367381","issuer_name":"OCULAR THERAPEUTIX, INC","issuer_ticker":"OCUL","issuer_name_source":null,"issuer_url":"/issuer/0001367381","owner_cik":null,"owner_name":"SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.; SVLSF IV, LLC; SV LIFE SCIENCES FUND IV, L.P.; SV Life Sciences Fund IV (GP), L.P.","owner_display_name":"SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":362703.0,"shares_display":"362,703","price_per_share":22.0,"price_display":"22.00","price_state":"stated","total_value":7979466.0,"total_display":"7,979,466.00","total_whole":"7,979,466","shares_owned_after":2151523.0,"shares_owned_after_display":"2,151,523","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-06-10","filed_date":"2015-06-11","scope":"insider"}],"collapsed":true,"next_cursor":"2015-06-10|8793448","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001348911","name":"KalVista Pharmaceuticals, Inc.","url":"/issuer/0001348911","role":"Ten percent owner","n_filings":9,"first_seen":"2018-12-21","last_seen":"2019-04-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001374128","name":"ENTELLUS MEDICAL INC","url":"/issuer/0001374128","role":"Ten percent owner","n_filings":2,"first_seen":"2015-02-04","last_seen":"2017-02-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001393434","name":"OCULAR THERAPEUTIX, INC","url":"/issuer/0001393434","role":"Ten percent owner","n_filings":2,"first_seen":"2014-07-31","last_seen":"2015-06-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001410939","name":"Ophthotech Corp.","url":"/issuer/0001410939","role":"Ten percent owner","n_filings":6,"first_seen":"2014-02-19","last_seen":"2014-06-05"},{"type":"issuer","type_label":"ISSUER","cik":"0000876378","name":"TRANSENTERIX INC.","url":"/issuer/0000876378","role":"Ten percent owner","n_filings":1,"first_seen":"2014-04-23","last_seen":"2014-04-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001385830","name":"NeurogesX Inc","url":"/issuer/0001385830","role":"Ten percent owner","n_filings":2,"first_seen":"2009-09-17","last_seen":"2010-05-05"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001422339","retrieved_at":"2026-08-22T10:40:32+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}